# MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

> **NCT05877651** · PHASE1 · COMPLETED · sponsor: **HRYZ Biotech Co.** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** MASCT-I injection

## Key facts

- **NCT ID:** NCT05877651
- **Lead sponsor:** HRYZ Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-21
- **Primary completion:** 2021-10-15
- **Final completion:** 2021-10-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877651, "MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05877651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*